PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$126.84
-1.48 (-1.15%)
Financial Highlights (FY 2026)
Revenue
485.93M
Net Income
-97,434,771
Gross Margin
—
Profit Margin
-57.3%
Rev Growth
+13.4%
D/E Ratio
0.63
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 35.1% | 35.1% |
| Operating Margin | -69.5% | -62.6% | 16.9% | 20.8% |
| Profit Margin | -57.3% | -54.5% | 16.5% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 485.93M | 428.36M | 158.95M | 134.45M |
| Gross Profit | — | — | 55.78M | 47.18M |
| Operating Income | -337,772,779 | -267,979,108 | 26.92M | 27.98M |
| Net Income | -97,434,771 | -77,301,916 | 26.26M | 18.87M |
| Gross Margin | — | — | 35.1% | 35.1% |
| Operating Margin | -69.5% | -62.6% | 16.9% | 20.8% |
| Profit Margin | -57.3% | -54.5% | 16.5% | 14.0% |
| Rev Growth | +13.4% | +13.4% | +20.5% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 314.72M | 314.72M | 243.86M | 257.74M |
| Total Equity | 495.86M | 495.86M | 493.28M | 509.61M |
| D/E Ratio | 0.63 | 0.63 | 0.49 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -97,434,771 | -81,596,467 | 46.23M | 40.75M |
| Free Cash Flow | — | — | 10.92M | 9.19M |